ATE432984T1 - Von mage-10 oder mage-8 abgeleitete hla-a2.1- bindende oligopeptide - Google Patents

Von mage-10 oder mage-8 abgeleitete hla-a2.1- bindende oligopeptide

Info

Publication number
ATE432984T1
ATE432984T1 AT99958438T AT99958438T ATE432984T1 AT E432984 T1 ATE432984 T1 AT E432984T1 AT 99958438 T AT99958438 T AT 99958438T AT 99958438 T AT99958438 T AT 99958438T AT E432984 T1 ATE432984 T1 AT E432984T1
Authority
AT
Austria
Prior art keywords
mage
hla
binding oligopeptides
oligopeptides derived
derived
Prior art date
Application number
AT99958438T
Other languages
English (en)
Inventor
Lan-Qing Huang
Pel Aline Van
Francis Brasseur
Plaen Etienne De
Thierry Boon
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Application granted granted Critical
Publication of ATE432984T1 publication Critical patent/ATE432984T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
AT99958438T 1998-11-27 1999-11-26 Von mage-10 oder mage-8 abgeleitete hla-a2.1- bindende oligopeptide ATE432984T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9826143.1A GB9826143D0 (en) 1998-11-27 1998-11-27 Tumour rejection antigens
PCT/IB1999/002018 WO2000032769A2 (en) 1998-11-27 1999-11-26 Mage-10 or mage-8 derived hla-a2.1-binding oligopeptides

Publications (1)

Publication Number Publication Date
ATE432984T1 true ATE432984T1 (de) 2009-06-15

Family

ID=10843261

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99958438T ATE432984T1 (de) 1998-11-27 1999-11-26 Von mage-10 oder mage-8 abgeleitete hla-a2.1- bindende oligopeptide

Country Status (9)

Country Link
US (2) US7547439B1 (de)
EP (1) EP1131426B1 (de)
JP (1) JP2002531088A (de)
AT (1) ATE432984T1 (de)
AU (1) AU765669B2 (de)
DE (1) DE69940954D1 (de)
GB (1) GB9826143D0 (de)
HK (1) HK1043149A1 (de)
WO (1) WO2000032769A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1762575A1 (de) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identifizierung Tumor-assoziierter Antigene für Diagnoseund Therapie
WO2008053573A1 (fr) * 2006-10-30 2008-05-08 National University Corporation Hokkaido University Remède pour néoplasme malin
EP1970384A1 (de) 2007-03-14 2008-09-17 Ganymed Pharmaceuticals AG Monoklonale Antikörper zur Krebsbehandlung
EP2371864A1 (de) 2010-03-23 2011-10-05 Ganymed Pharmaceuticals AG Monoklonale Antikörper zur Krebsbehandlung
DK2663580T3 (en) * 2011-01-10 2017-03-13 Ct Atlantic Ltd COMBINATION THERAPY INCLUDING TUMOR ASSOCIATED ANTI-BINDING ANTIBODIES
US9290541B2 (en) 2011-11-18 2016-03-22 Board Of Regents, The University Of Texas System TCL1 peptides for immunotherapy
EP2982681B8 (de) 2013-03-29 2018-11-07 Sumitomo Dainippon Pharma Co., Ltd. Wt1-antigen-peptid-konjugat-vakzin
EP2980097A4 (de) * 2013-03-29 2017-03-08 Sumitomo Dainippon Pharma Co., Ltd. Konjugatimpfstoff mit trimmfunktion von erap1
SG10201805674YA (en) * 2014-01-02 2018-08-30 Memorial Sloan Kettering Cancer Center Determinants of cancer response to immunotherapy
US12383608B2 (en) 2016-11-30 2025-08-12 Sumitomo Pharma Co., Ltd. WT1 helper peptides and combinations of WT1 helper peptide and conjugate of cancer antigen peptides
WO2019139972A1 (en) 2018-01-09 2019-07-18 Board Of Regents, The University Of Texas System T cell receptors for immunotherapy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
JP3908271B2 (ja) * 1993-03-05 2007-04-25 エピミューン，インコーポレイティド Ｈｌａ−ａ２．１結合ペプチドおよびそれらの使用
US5554724A (en) 1994-03-24 1996-09-10 University Of Leiden Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof
US5686068A (en) 1994-03-24 1997-11-11 Ludwig Institute For Cancer Research Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof
US6682731B1 (en) * 1994-03-24 2004-01-27 Ludwig Institute For Cancer Research Isolated peptides derived from mage tumor rejection antigen precursors which complex with HLA-A2 molecules
US5851523A (en) * 1994-03-24 1998-12-22 Ludwig Institute For Cancer Research. Isolated, peptides derived from MAGE tumor rejection antigen precursors which complex with HLA-A2 molecules and uses thereof
WO1996010413A1 (en) * 1994-09-30 1996-04-11 Ludwig Institute For Cancer Research Compositions containing tumor rejection antigen precursors or tumor rejection antigens, and an adjuvant and/or growth factor
US5908778A (en) * 1996-10-03 1999-06-01 Ludwig Institute For Cancer Research Mage-10 encoding cDNA, the tumor rejection antigen precursor mage-10, antibodies specific to the molecule, and uses thereof
US5912143A (en) * 1996-12-27 1999-06-15 Incyte Pharmaceuticals, Inc. Polynucleotides encoding a human mage protein homolog
EP1064022A4 (de) 1998-03-13 2004-09-29 Epimmune Inc Hla-bindeproteine und deren verwendung
US6297364B1 (en) * 1998-04-17 2001-10-02 Ludwig Institute For Cancer Research Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof
WO1999061916A1 (en) 1998-05-29 1999-12-02 Epimmune, Inc. Identification of broadly reactive dr restricted epitopes

Also Published As

Publication number Publication date
WO2000032769A2 (en) 2000-06-08
DE69940954D1 (de) 2009-07-16
WO2000032769A3 (en) 2000-10-19
JP2002531088A (ja) 2002-09-24
AU765669B2 (en) 2003-09-25
US8519109B2 (en) 2013-08-27
GB9826143D0 (en) 1999-01-20
AU1580600A (en) 2000-06-19
US20090209034A1 (en) 2009-08-20
US7547439B1 (en) 2009-06-16
EP1131426B1 (de) 2009-06-03
HK1043149A1 (zh) 2002-09-06
EP1131426A2 (de) 2001-09-12

Similar Documents

Publication Publication Date Title
DK1265914T3 (da) WNT-1-relaterede polypeptider og nukleinsyrer, der koder for samme
DE69838143D1 (de) Antimikrobielle peptide
ATE338121T1 (de) Von muc-1 abgeleitete peptide
DE60141546D1 (de) Polypeptide enthaltend extrazellulären Domäne von IL-20RA und/oderr IL-20RB
CA2295219A1 (en) Integrin binding peptide and use thereof
DE69940954D1 (de) Von mage-10 oder mage-8 abgeleitete hla-a2.1-bindende oligopeptide
PL342568A1 (en) Deep-frozen article of food
NZ333606A (en) Isolated peptides derived from MAGE-2
FI961044A0 (fi) Kininogeeni-inhibiittorit
ATE223481T1 (de) Peptid der löslichen form von acetylcholinesterase mit aktivität als calciumkanalmodulator
ATE110742T1 (de) Peptid-verbindungen.
DE60114363D1 (de) Oligomere von konformationsbeschränkten, nicht-peptidischen di- oder tripeptid-mimetika, und ihre verwendung zur synthese von künstlichen polypeptiden und proteinen
PL342578A1 (en) Deep-frozen article of food
EP1006126A3 (de) Peptide mit osteogener Aktivität
ATE355302T1 (de) N-substituierte d-aminosäuren enthaltende peptide,zur prävention der beta-strang assoziation
EP1117682A4 (de) Peptide
ATE385805T1 (de) Neue peptide
ATE393224T1 (de) Nukleinsäuresequenzen von hyperplasien und tumoren der schilddrüse
DE59109235D1 (de) Peptide des HIV-gag Proteins, ihre Herstellung und Verwendung
EA200100314A1 (ru) Пептидные фрагменты холерного экзотоксина в или энтеротоксина в в качестве адъювантов вакцины
DE69635457D1 (de) Deprenyl induziertes protein
FR2654430B1 (fr) Nouveaux derives de peptides, utilisables comme inhibiteurs des collagenases bacteriennes.
ES2232556T3 (es) Polipeptidos y acidos nucleicos que codifican estos.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1131426

Country of ref document: EP